Document is current
Any future updates will be listed below
-
Authors
Fiorenza, Salvatore
Ritchie, David S.
Ramsey, Scott D.
Turtle, Cameron J.
Roth, Joshua A. https://orcid.org/0000-0001-6621-8342
-
Funding
Funding for this research was provided by:
Gilead Sciences
Fred Hutchinson Cancer Research Center
- License Information
-
More Information
Article History
Received: 5 February 2020
Revised: 13 May 2020
Accepted: 18 May 2020
First Online: 30 May 2020
Compliance with ethical standards
:
: SF and DSR declare no conflicts of interest. CJT is an inventor on patents licensed or pending to Juno Therapeutics (a Bristol-Myers Squibb company) and Nektar Therapeutics; receives research funding from Juno Therapeutics (a Bristol-Myers Squibb company) and Nektar Therapeutics; has equity options in Precision Biosciences, Caribou Biosciences, and Eureka Therapeutics; and has served as an advisor for Juno Therapeutics (a Bristol-Myers Squibb company), Nektar Therapeutics, Precision Biosciences, Caribou Biosciences, Eureka Therapeutics, Allogene, Kite Pharma (a Gilead company), Novartis, Humanigen, Aptevo, and Allogene. JAR and SDR have served as consultants for Kite Pharma (a Gilead company).
